A virtual roundtable discussion with noted investigators Prof
Claire Harrison and Dr John Mascarenhas for a review of recent
innovations in the treatment of myeloproliferative neoplasms.
Biology of myeloproliferative neoplasms (MPN); mutational
landscape and implications for prognosis and therapy (00:00)
Diagnosis and risk stratification of MPN (3:34)
Pathophysiology of MPN and therapeutic approach to patients
with MPN (6:41)
Case (Prof Harrison): A man in his early 60s
with symptomatic primary myelofibrosis (MF) and mutations in JAK2,
ASXL1, EZH2 and TET2 receives ruxolitinib as first-line therapy
(9:39)
Dosing and quality of life with ruxolitinib (11:58)
Case (Dr Mascarenhas): A man in his early 60s
receives ruxolitinib for symptomatic primary MF and experiences a
return of symptoms 3 years later (14:14)
Bone pain associated with MF; use of bone marrow biopsy to
monitor disease progression (16:41)
Design, eligibility criteria and results of the Phase III
COMFORT-I and COMFORT-II studies evaluating ruxolitinib for
patients with MF (21:16)
A pooled analysis of overall survival in the COMFORT-I and
COMFORT-II trials of ruxolitinib for the treatment of MF
(23:53)
Predictors of overall survival benefit with ruxolitinib
(26:01)
Biologic rationale for the survival benefit with ruxolitinib in
MF (28:50)
Perspective on the use of ruxolitinib in patients with MF in
the absence of symptoms (32:56)
Side-effect profile of ruxolitinib (36:36)
Management of cytopenias associated with ruxolitinib
(40:33)
Potential correlation between JAK inhibitor therapy and second
primary cancers (42:13)
Spectrum of activity and ongoing investigation of novel JAK
inhibitors in MF (45:21)
Efficacy of fedratinib, pacritinib and momelotinib in patients
with MF (48:08)
Activity and tolerability of fedratinib for MF (50:45)
Results of the single-arm, Phase II JAKARTA-2 study evaluating
fedratinib in patients with MF previously treated with ruxolitinib
(52:51)
Response to fedratinib in the JAKARTA-2 study; ongoing Phase
III studies of fedratinib in the second-line setting for MF
(55:49)
Case (Prof Harrison): A man in his late 60s
with triple-negative primary MF experiences a good response to
fedratinib as second-line therapy on the JAKARTA-2 trial
(1:00:13)
Case (Dr Mascarenhas): A man in his early 70s
with primary MF and cytopenias experiences an improvement in
symptoms and reduction in spleen size after treatment with
pacritinib on the PERSIST-2 study
(1:03:23)
Potential role of fedratinib, pacritinib and momelotinib in the
management of MF (1:05:11)
Ongoing investigation of erythroid maturation agents in
patients with MF (1:09:09)
Perspective on the role of luspatercept and sotatercept in the
management of MF (1:11:09)
Case (Prof Harrison): A man in his late 50s
with severe pruritus associated with polycythemia vera (PV)
experiences a dramatic relief of symptoms with ruxolitinib
(1:13:11)
Efficacy of ruxolitinib in managing pruritus associated with PV
(1:15:39)
Case (Dr Mascarenhas): A woman in her late 60s
with essential thrombocythemia (ET) refuses cytoreductive therapy
(1:18:24)
Effect of age and mutational status on the decision to treat ET
(1:21:18)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.